Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Priti Lal, MD

Priti Lal, MD

faculty photo
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 2156626505
B.S. (Genetics)
Delhi University, Delhi, India, 1984.
Maulana Azad Medical College, Delhi, India, 1990.
Permanent link
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.

Description of Clinical Expertise

GU Pathology. Cardiovascular and renal transplantation pathology.
Breast Pathology

Selected Publications

Lal Priti, Salazar P, Chen B. : HER-2/neu testing in Breast Cancer: A single institution experience of 2279 cases. J of Molecular Diagnostics 5(4): Pg 279, Nov 2003.

Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123(4): 541-6, 2005.

Holzbeierlein, J, Lal, Priti, LaTulippe E, Smith A, Satagopan J, Zhang L,Ryan C, Smith S, Scher H, Scardino P, Reuter VE, Gerald WL.: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and multiple complimentary mechanisms of therapy resistance. American Journal of Pathology, 164 (1): 217-227, 2004.

Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. : HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6): 435-46, December 2008.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity. Cancer Discov 4(1): 53-60, Jan 2014 Notes: Co-Senior Author.

Charles J Ryan, Alex Smith, Priti Lal, Jaya Satagopan, Victor Reuter, Peter Scardino, William Gerald, Howard I Scher : Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology. 68(4): 834-9 October 2006

David Vaughn, Keith Flaherty, Priti Lal, Maryann Gallagher, Peter O'Dwyer: Treatment of Growing Teratoma Syndrome. NEJM 360(4): 423-424, January 2009.

Vaughn DJ, Gallagher M, Lal P, Rosen MA, Hwang W, Einhorn LH, O'Dwyer PJ: : Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors. Cancer Research 30, 2012 Notes: Poster presentation at ASCO 2012.

Renee Frank, MD1, Maria R Molina, MSN, CRNP2, Joyce W Wald, DO2, Lee R Goldberg, MD, MPH2, Malek Kamoun, MD, PhD1 and Priti Lal, MD1: Correlation of Circulating Donor Specific Anti-HLA Antibodies and Presence of C4d in Endomyocardial Biopsy with Heart Allograft Outcomes: A Single Center Retrospective Study. Journal of Heart Lung Transplant 32(4): 410-7, April 2013 Notes: Senior and corresponding author.

Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas; : Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). ASCO 2014.

Gregory T. Motz, Li-Ping Wang, Stephen P. Santoro,Tom Garrabrant,Ricardo R. Lastra, Ian S. Hagemann, Priti Lal, Michael D. Feldman, Fabian Benencia,and George Coukos: Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors. Nature Medicine 2014.

back to top
Last updated: 03/17/2015
The Trustees of the University of Pennsylvania